Literature DB >> 11390450

TAP-independent presentation of CTL epitopes by Trojan antigens.

J Lu1, P J Wettstein, Y Higashimoto, E Appella, E Celis.   

Abstract

The majority of CTL epitopes are derived from intracellular proteins that are degraded in the cytoplasm by proteasomes into peptides that are transported into the endoplasmic reticulum by the TAP complex. These peptides can be further processed into the optimal size (8-10 residues) for binding with nascent MHC class I molecules, generating complexes that are exported to the cell surface. Proteins or peptides containing CTL epitopes can be introduced into the cytoplasm of APCs by linking them to membrane-translocating Trojan carriers allowing their incorporation into the MHC class I Ag-processing pathway. The present findings suggest that these "Trojan" Ags can be transported into the endoplasmic reticulum in a TAP-independent way where they are processed and trimmed into CTL epitopes. Furthermore, processing of Trojan Ags can also occur in the trans-Golgi compartment, with the participation of the endopeptidase furin and possibly with the additional participation of a carboxypeptidase. We believe that these findings will be of value for the design of CTL-inducing vaccines for the treatment or prevention of infectious and malignant diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11390450     DOI: 10.4049/jimmunol.166.12.7063

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.

Authors:  Caroline J Voskens; Duane Sewell; Ronna Hertzano; Jennifer DeSanto; Sandra Rollins; Myounghee Lee; Rodney Taylor; Jeffrey Wolf; Mohan Suntharalingam; Brian Gastman; John C Papadimitriou; Changwan Lu; Ming Tan; Robert Morales; Kevin Cullen; Esteban Celis; Dean Mann; Scott E Strome
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

2.  Penetratin tandemly linked to a CTL peptide induces anti-tumour T-cell responses via a cross-presentation pathway.

Authors:  Dodie S Pouniotis; Vasso Apostolopoulos; Geoffrey A Pietersz
Journal:  Immunology       Date:  2006-03       Impact factor: 7.397

3.  Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.

Authors:  Diego Marescotti; Federica Destro; Anna Baldisserotto; Mauro Marastoni; Giuseppe Coppotelli; Maria Masucci; Riccardo Gavioli
Journal:  Immunology       Date:  2009-11-16       Impact factor: 7.397

4.  DNA-vaccine platform development against H1N1 subtype of swine influenza A viruses.

Authors:  Huiling Wei; Stephen D Lenz; David H Thompson; Roman M Pogranichniy
Journal:  Viral Immunol       Date:  2012-07-20       Impact factor: 2.257

5.  DNA-epitope vaccine provided efficient protection to mice against lethal dose of influenza A virus H1N1.

Authors:  Huiling Wei; Stephen D Lenz; David H Thompson; Roman M Pogranichniy
Journal:  Viral Immunol       Date:  2014-01-09       Impact factor: 2.257

6.  Vaccine delivery by penetratin: mechanism of antigen presentation by dendritic cells.

Authors:  Dodie Pouniotis; Choon-Kit Tang; Vasso Apostolopoulos; Geoffrey Pietersz
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

7.  Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma.

Authors:  David A Rodeberg; Rebecca A Nuss; Carrie J Heppelmann; Esteban Celis
Journal:  Cancer Immunol Immunother       Date:  2004-11-20       Impact factor: 6.968

8.  Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes.

Authors:  David A Rodeberg; Rebecca A Nuss; Sherine F Elsawa; Esteban Celis
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

9.  Design of immunogenic and effective multi-epitope DNA vaccines for melanoma.

Authors:  Hyun-Il Cho; Esteban Celis
Journal:  Cancer Immunol Immunother       Date:  2011-09-14       Impact factor: 6.968

10.  A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines.

Authors:  He Zhou; Yunping Luo; Masato Mizutani; Noriko Mizutani; Jürgen C Becker; F James Primus; Rong Xiang; Ralph A Reisfeld
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.